Thus, we considered that IDH1-mutant cell lines, which usually grow much faster than the original tumor in the brain, may lose methylation preferentially in late-replicating regions and show a similar methylation profile as recurrent glioma samples. This evidence concerns the gene IDH1 and central nervous system cancer.